Highlights
This study uncovers a fundamental molecular mechanism linking LMNA sequence variations to cardiac dysfunction in Emery-Dreifuss muscular dystrophy. The research demonstrates that reduced WNT5a expression leads to RhoA signaling inactivation, causing actin depolymerization and resulting in nuclear envelope deformation, contractile dysfunction, and impaired connexin 43 trafficking. Pharmacological interventions targeting the WNT5a/RhoA/actin pathway effectively rescued pathogenic phenotypes in patient-derived cardiac cells.
Background
Emery-Dreifuss muscular dystrophy represents a rare yet clinically significant genetic disorder that manifests through a characteristic triad of early-onset joint contractures, progressive muscle atrophy, and potentially life-threatening cardiac abnormalities. While the muscular components of the disease have been recognized for decades, the cardiac manifestations—particularly the high incidence of atrioventricular block and ventricular tachycardia—pose the greatest threat to patient survival and quality of life.
Among individuals carrying sequence variations in the LMNA gene, which encodes the nuclear envelope proteins lamin A and C, cardiac involvement tends to be particularly severe. Clinical observations have documented that approximately 20% of these patients eventually require heart transplantation, underscoring the profound impact of this condition on cardiovascular health. Despite decades of clinical recognition, the precise molecular mechanisms by which LMNA sequence variations precipitate EDMD have remained largely enigmatic, representing a significant gap in our understanding that has impeded development of targeted therapeutic interventions.
The present study addresses this critical knowledge gap by leveraging advanced stem cell technologies and multi-omics approaches to delineate the pathophysiological cascade linking LMNA sequence variations to cardiac phenotypes. The research team, led by investigators at Peking University, employed patient-specific induced pluripotent stem cells, genome editing, and engineered cardiac tissues to comprehensively characterize disease mechanisms and evaluate potential treatment strategies.
Study Design
The investigation enrolled five clinically diagnosed EDMD patients harboring LMNA sequence variations, with patient-specific iPSCs generated using a nonintegrating Sendai virus approach to minimize genomic perturbations. Two healthy donor-derived iPSC lines served as controls, and genome editing was employed to correct the LMNA L204P sequence variation in patient lines, generating isogenic control pairs that enabled rigorous comparison.
Cardiomyocyte differentiation was accomplished through a monolayer-based protocol, and three-dimensional engineered heart tissues were constructed in strip format capable of generating measurable contractile force. A knock-in mouse model carrying the Lmna L204P sequence variation was also generated to validate findings in a whole-organism context. Multi-omics analyses, including chromatin accessibility studies, were performed to identify downstream targets of LMNA sequence variations.
Key Findings
Multilineage Phenotypic Characterization
Comparative analysis of patient-derived iPSC-CMs revealed a constellation of disease-relevant phenotypes absent in control and gene-corrected lines. EDMD-specific cardiomyocytes exhibited marked disorganization of sarcomeric structures, abnormal nuclear envelope morphology, propensity for arrhythmias, and significantly impaired contractile function. These findings establish the fidelity of the iPSC model system and confirm that the L204P sequence variation is sufficient to confer the disease phenotype.
WNT5a as a Direct LMNA Target
Multi-omics investigation uncovered a previously unrecognized regulatory relationship between LMNA and WNT5a. Chromatin immunoprecipitation studies demonstrated direct binding of wild-type LMNA to the WNT5A promoter region. Critically, the Leu204Pro sequence variation was shown to reduce chromatin accessibility at this promoter, resulting in substantially diminished WNT5A transcription in patient-derived cardiomyocytes. This finding positions WNT5a as a key downstream effector whose dysregulation mediates LMNA-related cardiac pathology.
Actin Cytoskeleton Dysregulation Downstream of WNT5a/RhoA Signaling
Functional characterization revealed that WNT5a/RhoA signaling inactivation in EDMD cardiomyocytes leads to profound actin cytoskeleton abnormalities. Patient cells demonstrated evidence of actin depolymerization coupled with inhibition of actin polymerization, indicating that proper WNT5a signaling is essential for maintenance of actin filament homeostasis in cardiac myocytes. This cytoskeletal disruption carries multiple downstream consequences critical to cardiac function.
Nuclear Envelope Deformation and Cx43 Trafficking Impairment
The actin cytoskeletal abnormalities resulting from WNT5a/RhoA inactivation precipitated two mechanistically linked pathogenic outcomes. First, nuclear envelope structure became deformed, reflecting the importance of actin-based nuclear positioning and envelope integrity in cardiomyocytes. Second, trafficking of connexin 43—the gap junction protein essential for electrical coupling between cardiac myocytes—became impaired, resulting in reduced distribution of Cx43 at cell-cell borders. This Cx43 mislocalization provides a direct mechanistic explanation for the arrhythmic phenotype observed in EDMD cardiomyocytes.
Pharmacological Rescue of Disease Phenotypes
Perhaps the most clinically significant finding involves the demonstration that multiple pharmacological interventions successfully rescue EDMD phenotypes. Exogenous WNT5a supplementation, RhoA activators, and actin polymerization stabilizers each alleviated pathogenic abnormalities in patient-derived cardiomyocytes. Engineered heart tissues displaying dysfunctional contractile force generation showed significant improvement following RhoA activator treatment. These findings identify three distinct therapeutic entry points for potential clinical development.
In Vivo Validation in Knock-In Mouse Model
Lmna L204P heterozygous knock-in mice exhibited progressive cardiac dysfunction and developed cardiac arrhythmias specifically in response to sympathetic stress, recapitulating key features of human EDMD cardiac involvement. This validates the mechanistic findings in a whole-organism context and provides an essential preclinical platform for evaluating therapeutic strategies.
Mechanistic Implications
The study substantially advances our understanding of LMNA-related cardiac disease by establishing a clear mechanistic pathway from gene variant to cellular phenotype. The identification of WNT5a as a direct transcriptional target of LMNA resolves a fundamental question regarding the downstream effectors of nuclear envelope dysfunction. Furthermore, the demonstration that actin cytoskeletal dynamics represent a critical nexus linking nuclear envelope abnormalities to functional cardiac phenotypes provides a unifying framework for understanding diverse manifestations of EDMD.
The observation that Cx43 trafficking depends on intact WNT5a/RhoA/actin signaling offers particular mechanistic insight. Gap junction dysfunction represents a well-established contributor to arrhythmogenesis in multiple cardiac conditions, and this study identifies LMNA sequence variations as a previously unrecognized cause of Cx43 mislocalization. This finding may have implications extending beyond EDMD to other conditions characterized by nuclear envelope dysfunction.
Clinical and Therapeutic Implications
The identification of three distinct pharmacological targets—WNT5a signaling, RhoA activation, and actin polymerization—provides multiple potential entry points for therapeutic development. Unlike approaches requiring gene therapy or genome editing, these targets may be addressable through conventional small-molecule pharmacology, potentially accelerating clinical translation. The demonstration that pharmacological interventions effectively rescue phenotypes in engineered heart tissues provides essential proof-of-concept for this therapeutic strategy.
The knock-in mouse model generated in this study represents a valuable resource for preclinical evaluation of candidate therapies. The observation that arrhythmias emerge specifically in response to sympathetic stress mirrors the clinical experience in EDMD patients, where physical or emotional stress often triggers arrhythmic events.
Study Limitations and Considerations
Several limitations warrant consideration when interpreting these findings. The patient cohort, while appropriately characterized, remains relatively small due to the rarity of EDMD. Validation in larger patient cohorts would strengthen confidence in the generalizability of findings. The study focuses specifically on the L204P variant, and it remains to be determined whether findings extend to other LMNA sequence variations associated with EDMD.
While engineered heart tissues provide valuable physiological readouts, they cannot fully replicate the complexity of the intact human heart. Translation to clinical benefit will require additional studies in larger animal models and careful evaluation of potential off-target effects of pharmacological interventions.
Conclusion
This landmark study establishes WNT5a-mediated aberrant actin filament dynamics as a fundamental mechanism underlying cardiac pathogenic phenotypes in LMNA-related Emery-Dreifuss muscular dystrophy. The demonstration that WNT5a/RhoA signaling inactivation drives actin depolymerization, leading to nuclear envelope deformation, contractile dysfunction, and impaired Cx43 trafficking, identifies multiple actionable therapeutic targets. The successful pharmacological rescue of disease phenotypes in patient-derived cells provides compelling proof-of-concept for a novel treatment approach that may ultimately transform outcomes for patients with this devastating condition. These findings represent a paradigm shift in our understanding of nuclear envelope-associated cardiac disease and open avenues for targeted therapeutic intervention.
Funding
This study was supported by the National Key R&D Program of China and the National Natural Science Foundation of China.
References
1. Fan H, Wang X, Liu X, et al. WNT5a-Mediated Aberrant Actin Filament Dynamics Drive Cardiac Pathogenic Phenotypes in LMNA-Related Emery-Dreifuss Muscular Dystrophy. Circulation. 2026. PMID: 41993022.
